Transplantation tolerance: a journey from ignorance to memory

atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr–/– mice. FASEB J 2001; 15: 2730–2732 13. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17–e24 14. Mostafa ME, Chollet-Martin S, Oudghiri M et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion andMMP-9/TIMP-1 secretion.Cardiovasc Res 2001; 49: 882–890 15. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96: 2304–2310 16. Waehre T, Halvorsen B, Damas JK et al. Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 2002; 32: 803–810 17. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746–749 18. Turner DM, Williams DM, Sankaran D et al. An investigation of polymorphism in the interleukin-10 gene promotor. Eur J Immunogen 1997; 24: 1–8 19. Koch W, Kastrati A, Bottiger C et al. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001; 159: 137–144 20. Donger C, Georges JL, Nicaud V et al. New polymorphisms in the interleukin-10 gene—relationships to myocardial infarction. Eur J Clin Invest 2001; 31: 9–14 21. Canivet E, Lavaud S, Wong T et al. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994; 23: 41–46 22. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107–114 23. Girndt M, Sester U, Kaul H, Köhler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single cell level. J Am Soc Nephrol 1998; 9: 1689–1696 24. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112–S119 25. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–658 26. Girndt M, Köhler H, Schiedhelm Weick E et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559–565 27. Morita Y, Yamamura M, Kashihara N, Makino H. Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. Res Commun Mol Pathol Pharmacol 1997; 98: 19–33 28. Brunet P, Capo C, Dellacasagrande J et al. IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1745–1751 29. Girndt M, Sester U, Sester M et al. The interleukin-10 promotor genotype determines clinical immune function in hemodialysis patients. Kidney Int 2001; 60: 2385–2391 30. Girndt M, Kaul H, Sester U et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002; 62: 949–955